Nephromag (Buffered Phosphate Solution | Mertiatide)

• Nephromag (Buffered Phosphate Solution) is used in medical contexts where phosphate homeostasis is a concern.
• Hypophosphatemia: Restores plasma phosphate levels in patients with low serum phosphate.
• Renal replacement therapy: Maintains phosphate balance during dialysis or continuous renal replacement procedures.
• Peri‑operative care: Prevents phosphate depletion associated with major surgery or intensive care stays.

• The solution provides phosphate ions in a physiologically buffered medium, allowing rapid diffusion into the extracellular compartment after intravenous infusion. The buffering agents maintain a near‑neutral pH, minimizing irritation and supporting the re‑establishment of normal phosphate concentrations, which are essential for cellular energy metabolism, bone mineralization, and acid‑base balance.

Nephromag may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects

• Injection site discomfort: Mild pain or irritation at the infusion site.
• Transient hyperphosphatemia: Temporary elevation of serum phosphate levels.
• Hypocalcemia: Reduced calcium levels due to phosphate binding.
• Nausea: Mild gastrointestinal upset.

Serious or Rare Side Effects

• Severe hyperphosphatemia: Can lead to calcium‑phosphate precipitation and organ dysfunction.
• Allergic reaction: Rash, itching, or anaphylaxis in susceptible individuals.
• Cardiovascular instability: Hypotension or arrhythmia during rapid infusion.

• When using Nephromag, clinicians should observe several precautionary measures to ensure patient safety.
• Baseline assessment: Measure serum phosphate before infusion.
• Calcium monitoring: Check calcium levels to avoid hypocalcemia.
• Renal function: Adjust dosing in patients with impaired kidney function.
• Cardiovascular status: Use cautiously in patients with cardiac disease.
• Pregnancy and lactation: Safety not established; weigh risks and benefits.
• Store at ambient temperature: Keep in original container, protect from light and moisture.

Nephromag can interact with other agents that affect mineral balance or renal handling of electrolytes.

Major Interactions (Avoid)

• Calcium‑containing products: Co‑administration may cause precipitation of calcium‑phosphate complexes.
• Aluminum‑containing antacids: Can bind phosphate and reduce its bioavailability.

Moderate Interactions (Monitor Closely)

• Vitamin D analogues: May increase intestinal phosphate absorption.
• Loop diuretics: May alter electrolyte balance, requiring monitoring.
• ACE inhibitors: Potential impact on renal phosphate handling, warranting observation.